Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
2015 StandoutNobel
The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
2008 Standout
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
2003
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Ovarian cancer: strategies for overcoming resistance to chemotherapy
2003
Breast cancer
2016 Standout
AMPK: guardian of metabolism and mitochondrial homeostasis
2017 Standout
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
ROS in cancer therapy: the bright side of the moon
2020 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Ovarian cancer
2014 Standout
Microtubules and resistance to tubulin-binding agents
2010
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
The mechanisms of action of metformin
2017 Standout
Current Management Strategies for Ovarian Cancer
2007
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Immunohistochemical Analysis of Drug Resistanceassociated Proteins in Ovarian Carcinomas
2000
CA 15-3: Uses and limitation as a biomarker for breast cancer
2010
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
2009
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base
2006
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon
2005
Cellular Fatty Acid Metabolism and Cancer
2013 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Repositioning metformin for cancer prevention and treatment
2013
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2010 Standout
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial
2011
Cisplatin: The first metal based anticancer drug
2019 Standout
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
Repurposing metformin for the prevention of cancer and cancer recurrence
2017
Investigational cancer drugs targeting cell metabolism in clinical development
2014
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Tumor Angiogenesis
2008 Standout
Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer
2005
Ovarian cancer: Epidemiology, biology, and prognostic factors
2000
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer
2006
A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry
2014 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Current Management Strategies for Ovarian Cancer
2007
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT
2007
Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer
2011
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
2005
Metaplastic Breast Cancer: Clinical Features and Outcomes
2005
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
2012
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
2009
Works of Saverio Danese being referenced
Metaplastic breast carcinoma: pathology and clinical outcome.
2003
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
2006
Effect of Different Doses of Metformin on Serum Testosterone and Insulin in Non-Diabetic Women With Breast Cancer: A Randomized Study
2012
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
2009
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients
2006
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
2004
Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design
2002
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol
1998
Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
2006